This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Faron Ventures Oy. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: Kati Elima: Innovator in Peptide Research
Introduction
Kati Elima is a notable inventor based in Turku, Finland. She has made significant contributions to the field of peptide research, particularly in the context of vascular adhesion proteins. Her work has implications for both pharmaceutical and diagnostic applications.
Latest Patents
Kati Elima holds 1 patent related to novel peptides discovered through the phage display technique. This invention focuses on peptides that bind to VAP-1 (Vascular Adhesion Protein-1). The peptides are derived from natural proteins present in individuals and are particularly relevant to the leukocyte surface protein. These peptides serve as ligands for the VAP-1 molecule, facilitating the binding of leukocytes to the vascular endothelium. Additionally, her invention encompasses pharmaceutical and diagnostic compositions aimed at targeting VAP-1 in vivo.
Career Highlights
Kati Elima is associated with Faron Ventures Oy, where she continues her research and development in peptide technology. Her innovative work has positioned her as a key figure in the scientific community, particularly in the study of vascular adhesion and its implications for health.
Collaborations
Kati has collaborated with esteemed colleagues such as Sirpa Jalkanen and Elina Kivi. Their combined expertise enhances the research efforts at Faron Ventures Oy and contributes to advancements in the field.
Conclusion
Kati Elima's contributions to peptide research and her innovative patent on VAP-1 binding peptides highlight her role as a significant inventor in the scientific community. Her work continues to pave the way for advancements in medical applications.